Annals of Oncology

Wisdom word Are drug companies manipulating publications? How the fascination of cannabis misleads journalists. Patients become anxious and medical care team is overwhelmed: Anxiety about tamoxifen once again. Annals is going well. Americans may finally be reimbursed by Medicare for oral chemotherapy. If this was our only anxiety about our adolescent kids? And which will be the next drug to go out of the market? Difficult times at Johns Hopkins. There are unsafe places, but maybe there is more to it than that... Undertreating cancer pain is a crime. Perhaps not everyone knows that...
pp. 1183-1187(5)

A.B. Miller, H. Bartsch, P. Boffetta, L. Dragsted and H. Vainio (eds), Biomarkers in Cancer Chemoprevention
pp. 1188-1188(1)
Author: Bouchardy C.

The potential and pitfalls for developing guidelines in oncology
pp. 1189-1190(2)
Author: Austoker J.

Is there quality in clinical benefit?
pp. 1191-1193(3)
Authors: Steer C.B.; Marx G.M.; Harper P.G.

D.C. Allen, Histopathology Reporting. Guidelines for Surgical Cancer
pp. 1194-1194(1)
Author: McArdle C.S.

Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
pp. 1195-1203(9)
Authors: Piccart M.J.; Lamb H.; Vermorken J.B.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer
pp. 1205-1207(3)
Author: ESMO Guidelines Task Force

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma
pp. 1209-1210(2)
Author: ESMO Guidelines Task Force

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin’s lymphoma
pp. 1211-1212(2)
Author: ESMO Guidelines Task Force

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease
pp. 1213-1214(2)
Author: ESMO Guidelines Task Force

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT)
pp. 1215-1216(2)
Author: ESMO Guidelines Task Force

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma
pp. 1217-1218(2)
Author: ESMO Guidelines Task Force

ESMO Recommendations for the application of haematopoietic growth factors (hGFs)
pp. 1219-1220(2)
Author: ESMO Guidelines Task Force

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine*
pp. 1221-1230(10)
Authors: Vansteenkiste J.F.; Vandebroek J.E.; Nackaerts K.L.; Weynants P.; Valcke Y.J.; Verresen D.A.; Devogelaere R.C.; Marien S.A.; Humblet Y.P.; Dams N.L.; Group T.L.L.C.

Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
pp. 1231-1238(8)
Authors: Skarlos D.V.; Samantas E.; Briassoulis E.; Panoussaki E.; Pavlidis N.; Kalofonos H.P.; Kardamakis D.; Tsiakopoulos E.; Kosmidis P.; Tsavdaridis D.; Tzitzikas J.; Tsekeris P.; Kouvatseas G.; Zamboglou N.; Fountzilas G.

The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma
pp. 1239-1245(7)
Authors: Soini Y.; Järvinen K.; Kaarteenaho-Wiik R.; Kinnula V.

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
pp. 1247-1254(8)
Authors: O’Shaughnessy J.A.; Blum J.; Moiseyenko V.; Jones S.E.; Miles D.; Bell D.; Rosso R.; Mauriac L.; Osterwalder B.; Burger H.-U.; Laws S.

A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer
pp. 1255-1257(3)
Authors: Skovsgaard T.; Davidson N.G.P.; Piccart M.J.; Richel D.J.; Bonneterre J.; Cirkel D.T.; Barton C.M.; Knight S.

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial
pp. 1259-1264(6)
Authors: Laufman L.R.; Spiridonidis C.H.; Pritchard J.; Roach R.; Zangmeister J.; Larrimer N.; Moore T.; Segal M.; Jones J.; Patel T.; Gutterman L.; Carman L.; Colborn D.; Kuebler J.P.

Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes
pp. 1265-1268(4)
Authors: Zelek L.; Barthier S.; Riofrio M.; Sevin D.; Fizazi K.; Spielmann M.

Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy
pp. 1269-1272(4)
Authors: Ulrich-Pur H.; Kornek G.V.; Fiebiger W.; Gedlicka C.; Raderer M.; Lenauer A.; Depisch D.; Lang F.; Pidlich J.; Scheithauer W.

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
pp. 1273-1279(7)
Authors: Beer T.M.; Pierce W.C.; Lowe B.A.; Henner W.D.

Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial
pp. 1281-1288(8)
Authors: Köstler W.J.; Brodowicz T.; Attems Y.; Hejna M.; Tomek S.; Amann G.; Fiebiger W.C.C.; Wiltschke C.; Krainer M.; Zielinski C.C.

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)
pp. 1289-1293(5)
Authors: Punt C.J.A.; Fumoleau P.; Walle B.v.d.; Faber M.N.; Ravic M.; Campone M.

Epidemiology and survival in patients with carcinoid disease in the Netherlands
pp. 1295-1300(6)
Authors: Quaedvlieg P.F.H.J.; Visser O.; Lamers C.B.H.W.; Janssen-Heijen M.L.G.; Taal B.G.

Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients
pp. 1301-1306(6)
Authors: Paolo A.D.; Danesi R.; Falcone A.; Cionini L.; Vannozzi F.; Masi G.; Allegrini G.; Mini E.; Bocci G.; Conte P.F.; Tacca M.D.

Male gonadal dysfunction in patients with Hodgkin’s disease prior to treatment
pp. 1307-1311(5)
Authors: Rueffer U.; Breuer K.; Josting A.; Lathan B.; Sieber M.; Manzke O.; Grotenhermen F.-J.; Tesch H.; Bredenfeld H.; Koch P.; Nisters-Backes H.; Wolf J.; Engert A.; Diehl V.

Non-Hodgkin’s lymphoma of the testis: A retrospective study of 84 patients treated in the French anticancer centres
pp. 1313-1319(7)
Authors: Lagrange J.-L.; Ramaioli A.; Theodore C.; Terrier-Lacombe M.-J.; Beckendorf V.; Biron P.; Chevreau C.; Chinet-Charrot P.; Dumont J.; Delobel-Deroide A.; D’Anjou J.; Chassagne C.; Parache R.-M.; Karsenty J.-M.; Mercier J.; Droz J.-P.

Small-cell carcinoma of the esophagus: Report of three cases and review of the literature with emphasis on therapy
pp. 1321-1325(5)
Authors: Madroszyk A.; Egreteau J.; Martin L.; Queneau P.E.; Bosset J.F.; Merrouche Y.

Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma
pp. 1327-1329(3)
Authors: Edwards M.J.J.; Walker R.; Vinnicombe S.; Barlow C.; MacCallum P.; Foran J.M.

Repetita iuvant – INTACC (Intergruppo Italiano Terapia Adiuvante Carcinoma del Colon)
pp. 1331-1331(1)
Authors: Costanzo F.D.; Gasperoni S.; Falcone A.; Dogliotti L.; Frassinetti L.; Bruzzi P.; Rosso R.

This letter was referred to the author, who responds as follows
pp. 1331-1331(1)
Author: Wils J.

V. T. DeVita, S. Hellman & S. A. Rosenberg (eds). Progress in Oncology 2001
pp. 1332-1332(1)
Author: Punt C.J.A.

Corrigendum – F. Bertolini, W. Mingrone, A. Alietti, P. F. Ferrucci, E. Cocorocchio, F. Peccatori, S. Cinieri, P. Mancuso, C. Corsini, A. Burlini, E. Zucca & G. Martinelli. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol 2001; 12 (7): 987-90.
pp. 1333-1333(1)

Corrigendum – B. Glimelius. Chemoradiotherapy for rectal cancer – is there an optimal combination? Ann Oncol 12 (8): 1039-45.
pp. 1334-1334(1)